Microbiotica closed £36 million in Series C financing to advance its MB310 ulcerative colitis treatment into Phase 2 clinical development.
- Amount
- $48M
- Stage
- Series C
- Announced
- 16 October 2026
- Lead
- British Business Bank
- Other investors
- Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, Seventure Partners
- Use of funds
- Advance MB310 into Phase 2 clinical development in ulcerative colitis.
- Checked
- Announced by the company